 |
市场调查报告书
商品编码
1110089
重组 DNA 技术市场：按产品类型、应用、地区 - 规模、份额、前景、机会分析，2022-2030Recombinant DNA Technology Market, by Product Type, by Application, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 |
||||||
重组 DNA (rDNA) 技术是一项新技术，它在药物开发、农业和研究等许多领域取得了进展。重组 DNA 技术引入了一类新的生物，称为转基因生物 (GMO) 或转基因生物 (LMO)。我们已成功开发转基因作物（BT 棉花）、克隆动物、生物农药、生物燃料和基因疗法。 RDNA技术刺激了生物製药行业向CAR-T细胞治疗、双特异性和单克隆抗体等多种rDNA产品的开发，从而推动了重组DNA技术市场的增长。此外，基因编辑系统CRISPR（Clustered Regularly Interspaced Short Palindromic Repeats）在稳定和增强免疫力方面发挥着重要作用，在疫苗和药物开发方面具有巨大潜力。
市场动态
预计联盟等无机战略的日益采用将在预测期内推动市场增长。例如，2020 年 9 月，国家生物技术信息中心发布的数据显示，总部位于印度的生物技术和生物製药公司 Serum Institute of India Pvt, Ltd. (SII) 和卫生部下属的城市研究医学研究委员会 (ICMR) 已合作进行两种全球候选疫苗的临床开发。第一个是ChAdOx1-S，一种由牛津大学/阿斯利康开发的非复制型病毒载体疫苗。该疫苗正在巴西进行 III 期临床试验。 ICMR 已在 14 个临床试验地点启动 II/III 期桥接研究。 ICMR-国家结核病研究所 (NIRT)（钦奈）是牵头机构。
此外，2020年9月，ICMR和Serum Institute of India Pvt.我们也在合作进行单位纳米颗粒佐剂疫苗的临床开发，我们计划在疫苗由SII生产后于2020年10月下旬开始临床试验.该试验由印度浦那的 ICMR-国家爱滋病研究所 (NARI) 领导。
本研究的主要特点
- 本报告深入分析了以 2021 年为基准年的预测期（2022-2030 年）的全球重组 DNA 技术市场、市场规模和復合年增长率 (CAGR%)。
- 解释不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
- 该研究还提供了有关市场驱动因素、抑制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
- 基于公司亮点、产品组合、关键亮点、财务业绩和战略等参数的全球重组 DNA 技术市场主要参与者的概况。
- 本次调查涵盖的主要公司包括 Thermo Fisher Scientific, Inc.、Biogen, Inc.、Sanofi Pasteur、Merck & Co., Inc.、Pfizer, Inc.、Profacgen、Amgen, Inc. 和 Monsanto Company
- 本报告中的见解将使营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
- 《全球重组 DNA 技术市场》报告面向行业内的各种利益相关者，包括投资者和供应商、产品製造商、分销商、新进入者和金融分析师。
- 利用用于分析全球重组 DNA 技术市场的各种战略矩阵促进利益相关方的决策。
内容
第 1 章目的和先决条件
- 调查目的
- 先决条件
- 缩写说明
第2章市场展望
- 举报内容
- 市场定义和范围
- 执行摘要
- 按产品类型划分的市场概况
- 市场快照：按应用
- 市场概况：按地区划分
- 连贯的机会图 (COM)
第 3 章市场动态、监管和趋势分析
- 市场动态
- 驱动程序
- 限制因素
- 市场机会
- 监管场景
- 主要亮点
- PEST 分析
- 流行病学
- 影响分析
- 对PORTER的分析
第 4 章重组 DNA 技术的全球市场 - 冠状病毒 (COVID-19) 大流行的影响
- 整体影响
- 政府举措
- COVID-19 对市场的影响
第 5 章全球重组 DNA 技术市场：按产品类型，2017-2030 年
- 重组蛋白药物
- 胰岛素
- 人类生长激素
- 促红细胞生成素
- 干扰素
- 凝血因子
- 集落刺激因子
- 融合蛋白
- 其他
- 疫苗
- 转基因作物
- 表达系统
- 原核细胞
- 哺乳动物细胞
- 酵母
- 昆虫
- 其他
- 细胞和基因治疗
- 基因编辑
第 6 章。全球重组 DNA 技术市场，按应用分列，2017-2030 年
- 治疗区
- 农业领域
- 调查
第 7 章。2017-2030 年全球重组 DNA 技术市场，按地区分列
- 北美
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲地区
- 欧洲
- 英国
- 德国
- 意大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 东盟
- 澳大利亚
- 韩国
- 其他亚太地区
- 中东
- 海合会
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中非
- 南非
第 8 章竞争格局
- 热图分析
- 公司简介
- Thermo Fisher Scientific, Inc.
- 百健公司
- 赛诺菲巴斯德
- 财务摘要
- 默克公司
- 财务摘要
- 辉瑞公司
- 财务摘要
- Profacgen
- 财务摘要
- 安进公司
- 财务摘要
- 孟山都公司
- 财务摘要
第9章章节
- 参考资料
- 研究方法介绍
- 关于出版商
Recombinant DNA (rDNA) technology is a novel technique that has led to advances in a number of different fields such as drug development, agriculture, and research. Recombinant DNA technology has introduced new classes of organisms namely genetically modified organism (GMO) or living modified organism (LMO). It can develop genetically modified crops (BT cotton), cloned animals, bio pesticides, biofuel, and gene therapy successfully. rDNA technology has triggered the biopharmaceutical industries towards the development of various rDNA products such as CAR-T cell therapy and bispecific and monoclonal antibodies, in turn, favoring the growth of the recombinant DNA technology market. Moreover, the gene-editing system -Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) - holds great potential for the development of vaccines and drugs, as it plays a major role in the stability and enhancement of immunity.
Market Dynamics
The increasing adoption of inorganic strategies such as partnership is expected to drive the market growth over the forecast period. For instance, in September 2020, according to the data published by the National Center for Biotechnology Information, Serum Institute of India Pvt., Ltd. (SII), a biotechnology and Biopharmaceutical Company based in India, and the Indian Council of Medical Research (ICMR), an autonomous organization under the Department of Health Research, partnered for the clinical development of two global vaccine candidates. The first one is ChAdOx1-S, which is a non-replicating viral vector vaccine developed by the University of Oxford/AstraZeneca. This vaccine is undergoing phase III clinical trials in Brazil. Phase II/III bridging studies have been initiated by ICMR at 14 clinical trial sites. ICMR-National Institute for Research in Tuberculosis (NIRT), Chennai is the lead institution.
Moreover, in September 2020, ICMR and Serum Institute of India Pvt., Ltd. (SII) have also partnered for the clinical development of a glycoprotein subunit nanoparticle adjuvanted vaccine, developed by Novavax, Inc., biotechnology company that develops vaccines to counter serious infectious diseases from the U.S. The trial will be initiated in the second half of October 2020 after the vaccine is manufactured by SII. The trial is led by ICMR-National AIDS Research Institute (NARI), Pune, India.
Key features of the study:
- This report provides an in-depth analysis of the global recombinant DNA technology market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global recombinant DNA technology market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc., and Monsanto Company
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global recombinant DNA technology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant DNA technology market
Detailed Segmentation:
- Global Recombinant DNA Technology Market, By Product Type:
- Recombinant Protein Drugs
- Insulin
- Human Growth Hormone
- Erythropoietin
- Interferon
- Blood Factors
- Colony Stimulating Factors
- Fusion Proteins
- Others
- Vaccines
- Genetically Modified Crops
- Expression Systems
- Prokaryotic Cells
- Mammalian Cells
- Yeats
- Insect
- Others
- Cell and Gene Therapy
- Gene Editing
- Recombinant Protein Drugs
- Global Recombinant DNA Technology Market, By Application:
- Therapeutics
- Agriculture
- Research
- Global Recombinant DNA Technology Market, By Region:
- North America
- By Country
- U.S.
- Canada
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Thermo Fisher Scientific, Inc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biogen, Inc.
- Sanofi Pasteur
- Merck & Co., Inc.
- Pfizer, Inc.
- Profacgen
- Amgen, Inc.
- Monsanto Company
- Thermo Fisher Scientific, Inc.*
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Application
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Regulatory Scenario
- Key Highlights
- PEST Analysis
- Epidemiology
- Impact Analysis
- PORTER's Analysis
4. Global Recombinant DNA Technology Market - Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Recombinant DNA Technology Market, By Product Type, 2017 - 2030, (US$ Billion)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
- Recombinant Protein Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
- Insulin
- Human Growth Hormone
- Erythropoietin
- Interferon
- Blood Factors
- Colony Stimulating Factors
- Fusion Proteins
- Others
- Vaccines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
- Genetically Modified Crops
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
- Expression Systems
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
- Prokaryotic Cells
- Mammalian Cells
- Yeats
- Insect
- Others
- Cell and Gene Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
- Gene Editing
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
6. Global Recombinant DNA Technology Market, By Application, 2017 - 2030, (US$ Billion)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
- Therapeutics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
- Agriculture
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
- Research
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
7. Global Recombinant DNA Technology Market, By Region, 2017 - 2030, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Thermo Fisher Scientific, Inc.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biogen, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi Pasteur
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overviews
- Market Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overviews
- Market Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overviews
- Market Strategies
- Profacgen
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overviews
- Market Strategies
- Amgen, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overviews
- Market Strategies
- Monsanto Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overviews
- Market Strategies
9. Section
- References
- Research Methodology
- About Us
